Cargando…
Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum
Heart failure (HF) is a complex syndrome caused by a variety of structural or functional cardiac abnormalities as a consequence of several involved pathophysiological pathways. In the last decades, left ventricular ejection fraction (LVEF) has represented the principal criterion used to stratify HF,...
Autores principales: | Gallo, Giovanna, Volpe, Massimo, Battistoni, Allegra, Russo, Domitilla, Tocci, Giuliano, Musumeci, Maria Beatrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419408/ https://www.ncbi.nlm.nih.gov/pubmed/34497530 http://dx.doi.org/10.3389/fphys.2021.652163 |
Ejemplares similares
-
The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020) -
Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
por: Wang, Youmeng, et al.
Publicado: (2022) -
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019) -
Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies
por: Tini, Giacomo, et al.
Publicado: (2023) -
Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study
por: Armentaro, Giuseppe, et al.
Publicado: (2022)